LAROSA, MADDALENA
 Distribuzione geografica
Continente #
NA - Nord America 2.528
AS - Asia 264
EU - Europa 246
AF - Africa 9
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 3.053
Nazione #
US - Stati Uniti d'America 2.526
CN - Cina 114
IT - Italia 110
SG - Singapore 92
SE - Svezia 31
FR - Francia 25
FI - Finlandia 22
GB - Regno Unito 21
IQ - Iraq 17
DE - Germania 15
VN - Vietnam 14
IN - India 10
EG - Egitto 9
IE - Irlanda 8
ES - Italia 5
NL - Olanda 5
ID - Indonesia 4
TH - Thailandia 4
AM - Armenia 2
BR - Brasile 2
EU - Europa 2
IR - Iran 2
RU - Federazione Russa 2
TR - Turchia 2
CA - Canada 1
CO - Colombia 1
JP - Giappone 1
KR - Corea 1
MX - Messico 1
NZ - Nuova Zelanda 1
PL - Polonia 1
RO - Romania 1
SA - Arabia Saudita 1
Totale 3.053
Città #
Fairfield 548
Chandler 266
Woodbridge 219
Ashburn 208
Seattle 204
Houston 198
Cambridge 183
Wilmington 157
Ann Arbor 134
Singapore 65
San Diego 54
Beijing 35
Medford 35
Princeton 35
Des Moines 22
Padova 19
Helsinki 17
Boardman 16
Dong Ket 14
Baghdad 13
Milan 13
Nanjing 12
Roxbury 12
Dearborn 9
New York 8
Santa Clara 8
Cagliari 6
Cairo 6
Dublin 6
Hefei 6
London 6
Bangkok 4
Guangzhou 4
Karbala 4
Kunming 4
Los Angeles 4
Paris 4
Madrid 3
Ningbo 3
Norwalk 3
Ogden 3
Pignone 3
Shenyang 3
Tianjin 3
Acton 2
Adana 2
Al Qahirah al Jadidah 2
Amsterdam 2
Bandung 2
Bologna 2
Brescia 2
Caorle 2
Chagrin Falls 2
Dallas 2
Ferrara 2
Haikou 2
Hangzhou 2
Hebei 2
Indore 2
Jiaxing 2
Kilburn 2
Linköping 2
Medan 2
Moscow 2
Muggiò 2
Nanchang 2
Redmond 2
Senago 2
Treviso 2
Trieste 2
Vasto 2
Vicenza 2
Vigo 2
Washington 2
Yerevan 2
Bangalore 1
Baotou 1
Bogotá 1
Bucharest 1
Cinisi 1
Dobbs Ferry 1
Edinburgh 1
Ergolding 1
Falkenstein 1
Hounslow 1
Indiana 1
Ismailia 1
Jeddah 1
Jinan 1
Lappeenranta 1
Las Vegas 1
Milton Keynes 1
Pasadena 1
Pasian di Prato 1
Pellestrina 1
Phoenix 1
Pune 1
Ravenna 1
Redwood City 1
Rio de Janeiro 1
Totale 2.666
Nome #
Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. 174
Derivation and validation of the SLE Disease Activity Score (SLE-DAS): A new SLE continuous measure with high sensitivity for changes in disease activity 161
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 158
Advances in the Diagnosis and Classification of Systemic Lupus Erythematosus 150
Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission 138
IL-12 and IL-23/Th17 axis in systemic lupus erythematosus 121
Therapy of scleroderma renal crisis: State of the art 119
Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: A literature review 118
Diagnostic and prognostic role of renal histopathology in rheumatic diseases 113
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus 111
An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases. 110
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients 109
Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies 104
Can we manage lupus nephritis without chronic corticosteroids administration? 101
Clinical outcomes and predictors of maternal and fetal complications in pregnancies of patients with systemic lupus erythematosus 100
Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment 96
Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies. 87
Belimumab: a step forward in the treatment of systemic lupus erythematosus 86
“Disease knowledge index” and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases 81
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission 74
Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies 69
THE ROLE OF PENTRAXIN-3 AS PREDICTOR OF PREGNANCY COMPLICATIONS IN PATIENTS WITH SLE AND/OR ANTI-PHOSPHOLIPID SYNDROME AND APL CARRIERS 66
Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion 65
Generalized annular granuloma associated with crowned dens syndrome, which resolved with colchicine treatment. 61
Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals 58
Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients 57
Are remission and low disease activity state ideal targets for pregnancy planning in Systemic Lupus Erythematosus? A multicentre study 56
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 55
Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis 53
SLE-DAS in the First Trimester of Gestation Predicts Maternal Lupus Flares Later in Pregnancy 47
Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity 46
Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study 34
The Management of Systemic Lupus Erythematosus (SLE) Patients in Remission 33
Definition of Low Disease Activity State based on the SLE-DAS: Derivation and validation in a multicentre real-life cohort 27
SLE-DAS in the First Trimester of Gestation Predicts Maternal Lupus Flares Later in Pregnancy 22
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS) 21
Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in lupus women: the French GR2 study 19
Complement levels during the first trimester predict disease flare and adverse pregnancy outcomes in systemic lupus erythematosus: A network meta-analysis on 532 pregnancies 10
Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients 5
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study 4
Totale 3.119
Categoria #
all - tutte 12.213
article - articoli 12.023
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.236


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020675 0 0 0 199 66 55 70 69 70 64 42 40
2020/2021671 14 44 19 25 7 7 11 55 45 140 67 237
2021/2022590 26 59 69 15 41 74 45 43 23 40 40 115
2022/2023422 94 51 15 76 51 46 11 27 33 2 11 5
2023/2024284 9 27 26 24 9 67 26 14 20 12 19 31
2024/2025144 5 52 54 33 0 0 0 0 0 0 0 0
Totale 3.119